TABLE 4.
Baseline characteristics of patients based on the estimated glomerular filtration rate (eGFR) (n = 421).
|
eGFR(mL/min/l.73m2) |
|||
| >60 (n = 345) | <60 (n = 76) | P-value | |
| Sex(M:F) | I.5:1 | 1.30:1 | 0.588 |
| Age (Yrs) | 56.36 ± 11.11 | 66.03 ± 9.85 | < 0.001 |
| BMI (Kg/m2) | 24.99 ± 7.47 | 23.84 ± 3.43 | 0.070 |
| Diabetes duration (Yrs) | 7.16 ± 7.22 | 13.69 ± 9.37 | < 0.001 |
| HTN(n(%)) | 180 (53.4) | 62 (82.7) | < 0.001 |
| FPG(mg/dL) | 165.64 ± 52.34 | 176.35 ± 67.27 | 0.299 |
| HbAlc(%) | 8.19 ± 2.02 | 8.77 ± 2.67 | 0.098 |
| HOMA-IR | 4.52 ± 3.79 | 4.51 ± 2.50 | 0.981 |
| HOMA-B | 48.19 ± 37.72 | 46.89 ± 46.92 | 0.860 |
| Hb (g/dL) | 14.37 ± 1.54 | 12.51 ± 1.86 | < 0.001 |
| T-Cho (mg/dL) | 181.27 ± 44.23 | 173.26 ± 55.29 | 0.241 |
| HDL-Cho (mg/dL) | 51.76 ± 13.91 | 47.10 ± 15.54 | 0.020 |
| LDL-Cho (mg/dL) | 96.12 ± 38.66 | 90.04 ± 46.38 | 0.299 |
| TG(mg/dL) | 169.61 ± 110.06 | 184.16 ± 114.05 | 0.322 |
| ESR(mm/H) | 20.01 ± 20.83 | 40.67 ± 28.80 | < 0.001 |
| hsCRP (mg/dl.) | 0.28 ± 0.71 | 0.57 ± 1.30 | 0.099 |
| Fibrinogen (mg/dL) | 311.21 ± 54.78 | 338.44 ± 58.57 | 0.018 |
| CS5(mPa) | 317.43 ± 125.11 | 385.22 ± 182.89 | < 0.001 |
| EI@3Pa (%) | 30.60 ± 1.91 | 30.42 ± 20.54 | 0.481 |
| Fibrinogen/EI@3Pa (mg/dI.%) | 1033.28 ± 197.76 | 1141.44 ± 268.71 | 0.045 |
| DR(%) | 32.0 | 46.5 | 0.019 |
| DPN(%) | 15.4 | 29.3 | 0.004 |
| CAD(%) | 8.4 | 23.7 | < 0.001 |
BMI, body mass index; CAD, coronary artery disease; CSS, critical shear stress; DPN, diabetic peripheral neuropathy; DR, diabetic retinopathy; EI@3Pa, elongation index at 3 pascal; ESR, erythrocyte sedimentation rate; FPG, fasting plasma glucose; Hb, hemoglobin; HbA1c, glycated hemoglobin; HDL/LDL-cho, high/low density lipoprotein cholesterol; HOMA-IR/B, homeostasis model assessment of insulin resistance/beta-cell function; hs-CRP, high sensitivity c-reactive protein; HTN, hypertension; T-cho, total-cholesterol; TG, triglyceride (reproduced under CC BY 4.0 with permission from Chung et al. (2018).